Article info
PDFOvarian Cancer
Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study
- Address correspondence and reprint requests to Ritu Salani, MD, MBA, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, The Ohio State University, 320 W 10th Ave, M210 Starling Loving, Columbus, OH 43210. E-mail: ritu.salani{at}osumc.edu.
Citation
Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study
Publication history
- Received October 10, 2013
- Accepted January 14, 2014
- First published May 1, 2014.
Online issue publication
June 18, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.